Coronavirus information from UCLA and UCLA Health.


The Next Generation Incubator

Myst Therapeutics, Inc. is developing novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to destroy solid tumor cancer cells.


Myst Therapeutics is developing the next generation of cellular immunotherapies that will treat solid tumors, a massive unmet need as nearly all epithelial cancer patients have an expected survival of less than 12 months. For each patient, Myst Therapeutics selects the unique repertoire of immune cells that will recognize and target the specific mutations of their tumors. Myst then grows and rejuvenates those cells outside the body and reintroduces them in sufficient number and strength to destroy the tumor. Myst Therapeutics was acquired by Turnstone Bio in 2020.

Graduated: 2021
Location: San Diego, CA